Poly Medicure share price
NSE: POLYMEDBSE: 531768Healthcare Equipment & SuppliesSmall Cap
Poly Medicure Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 1996 on BSE, Dec 2011 on NSE
Last close ₹1,449.50down ₹12.40 (0.85%)BSE ₹1,447.90
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,461.90.
30 Oct: open ₹1,462.30, high ₹1,478.60, low ₹1,432.60
52-week range of traded prices to 30 Oct 2026
₹1,182.00Low, 30 Mar 2026₹2,094.30High, 11 Nov 2025
- Next results date: the board meets on 5 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹14,692 Cr425th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 46.63
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.73
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.24%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 9.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.11
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 68,60754.1% delivered
About Poly Medicure
Poly Medicure Limited is an Indian maker of medical devices used in infusion therapy (giving fluids and medicines through a vein), renal care, critical care, cardiology and orthopaedics.123 It makes them at plants in India, China, Italy, the Netherlands and Egypt and earns a large part of its revenue from exports.45
Its products include safety IV cannulas, dialysis machines and blood bags, and its orthopaedic implant lines include Xframe, Xfix and Dolphix.67 It reports its results as a single business segment, medical devices.8 Its subsidiaries include Poly Medicure (Laiyang) in China and Plan1 Health in Italy, and it holds a stake in Ultra for Medical Products, an associate company in Egypt.9
Himanshu Baid founded the company in 1995 and is its managing director.10 It raised ₹4 billion in 2021 and ₹10 billion in 2024 by placing shares with institutional investors.3 The promoter group, which includes Himanshu Baid, joint managing director Rishi Baid, director Jugal Kishore Baid and executive director Vishal Baid, held 62.42% of the shares at 30 Jun 2026.1112
Poly Medicure key points
Results
- In the quarter to Jun 2026, consolidated revenue rose 30.3% to ₹525 crore, of which ₹72.3 crore came from acquired businesses, and operating EBITDA rose 17.7% to ₹126.7 crore, a 24.1% margin.13
- In the year to Mar 2026, consolidated revenue from operations rose 12.3% to ₹1,87,525.9 lakh, and operating EBITDA (profit before interest, tax, depreciation and amortisation, excluding other income) was ₹45,770.0 lakh, a 24.4% margin, against ₹45,856.6 lakh a year earlier.14
- Consolidated profit after tax for the year to Mar 2026 fell to ₹32,073.0 lakh from ₹33,855.7 lakh, after one-off costs of the new labour codes and of acquisitions.14
- The company says it was the first Indian company to make dialysis products in India.15
Revenue mix
- Consolidated revenue by product group, quarter to Jun 202616Infusion therapy was 50% of consolidated revenue.
Item quarter to Jun 2026 Infusion therapy ₹259.2 crore Other products ₹141.9 crore Orthopaedics ₹49.2 crore Renal care ₹43.2 crore Cardiology ₹28.6 crore - In the quarter to Jun 2026, cardiology revenue rose from ₹2.9 crore a year earlier, led by the PendraCare acquisition and growth in India.17
- In the quarter to Jun 2026, renal care revenue fell 3.8% under price pressure from Chinese makers in India; on the company's application, the government opened an anti-dumping probe (into imports sold below fair value) into dialyzers from China and Malaysia.1819
Where revenue comes from
- Consolidated revenue by region20
Item quarter to Jun 2026 quarter to Jun 2025 Rest of the world ₹188.8 crore ₹144.8 crore Europe ₹187.3 crore ₹130.3 crore India ₹146.0 crore ₹125.7 crore - In the quarter to Jun 2026, rest of the world revenue rose 30.3%, but 4.0% without acquisitions, as sales to the Middle East fell about 32% because of the crisis there.2122
- The company supplies more than 125 countries through more than 1,000 distributors; its products are registered in more than 100 countries.23
Plants and capacity
- The group has 15 plants in 5 countries; in India, its plants are at Faridabad in Haryana, Haridwar in Uttarakhand and Jaipur in Rajasthan.2425
- On its earnings call of 10 Aug 2026, the company said a new plant at Palwal near Faridabad, for orthopaedics and transfusion, should come online by Mar 2027, and a Noida cardiology plant should start commercially in the quarter to Jun 2027.2627
- On its earnings call of 10 Aug 2026, the company said it expects capital spending of ₹200 crore to ₹225 crore in the year to Mar 2027.28
Research and development
- In the quarter to Jun 2026, the company held 399 patents, had an R&D team of more than 90 people in India, Italy and the Netherlands, and launched 6 new products in infusion therapy and critical care.2930
- In its presentation of 7 Aug 2026, the company said more than 840 patients had enrolled in PACIFIER, a 2,000-patient clinical registry for its drug-eluting stent (a drug-coated mesh tube that holds a heart artery open), with full enrolment targeted by Mar 2027.31
What the company expects
- On its earnings call of 10 Aug 2026, the company said it expects consolidated revenue of ₹2,300 crore to ₹2,400 crore in the year to Mar 2027, including a full year of PendraCare and Citieffe, and a consolidated EBITDA margin of 23% to 25%.32
- On its earnings call of 10 Aug 2026, the company said it expects standalone revenue (Poly Medicure alone, without its subsidiaries) of ₹1,900 crore to ₹2,000 crore in the year to Mar 2027, with an EBITDA margin of 25% to 27%.33
- On its earnings call of 10 Aug 2026, the company said it aims to double revenue by the year to Mar 2030, through organic growth and acquisitions.34
Recent events
- On 25 Jun 2026, CRISIL Ratings revised the outlook on the company's AA- long-term bank loan rating (a view of its ability to repay debt) to Positive from Stable; rated bank facilities rose to ₹500 crore from ₹400 crore.35
- On 6 Nov 2025, the company completed the purchase of 100% of Citieffe, an Italian maker of implants for broken bones in the limbs that the company says ranks second in Italy and Mexico with about 12.0% market share.3637
- On 3 Sep 2025, the group acquired PendraCare, a Dutch developer and maker of guiding and diagnostic catheters (thin tubes used in heart procedures).3839
Litigation and regulatory matters
- As of its exchange filing of 16 Jun 2026, the company was challenging a 15 Jun 2026 order of a Delhi stamp duty authority holding it liable for ₹1,00,25,820 of alleged unpaid stamp duty on share allotments and a ₹1,50,00,000 penalty.40
- As of the annual report for the year to Mar 2026, a disputed customs duty demand of ₹849.03 lakh was under appeal before the Customs, Excise and Service Tax Appellate Tribunal.41
Last updated
All 41 sources, each with its page
- 1. Annual report, 14 Aug 2026, page 116
- 2. Investor presentation, 7 Aug 2026, page 9
- 3. Investor presentation, 7 Aug 2026, page 11
- 4. Annual report, 14 Aug 2026, page 35
- 5. Annual report, 14 Aug 2026, page 36
- 6. Investor presentation, 7 Aug 2026, page 5
- 7. Investor presentation, 7 Aug 2026, page 5
- 8. Annual report, 14 Aug 2026, page 130
- 9. Annual report, 14 Aug 2026, page 33
- 10. Annual report, 14 Aug 2026, page 52
- 11. Annual report, 14 Aug 2026, page 53
- 12. Investor presentation, 7 Aug 2026, page 29
- 13. Earnings call, 10 Aug 2026, page 4
- 14. Annual report, 14 Aug 2026, page 32
- 15. Investor presentation, 7 Aug 2026, page 8
- 16. Investor presentation, 7 Aug 2026, page 28
- 17. Earnings call, 10 Aug 2026, page 4
- 18. Earnings call, 10 Aug 2026, page 4
- 19. Investor presentation, 7 Aug 2026, page 28
- 20. Investor presentation, 7 Aug 2026, page 27
- 21. Earnings call, 10 Aug 2026, page 4
- 22. Investor presentation, 7 Aug 2026, page 27
- 23. Investor presentation, 7 Aug 2026, page 6
- 24. Investor presentation, 7 Aug 2026, page 6
- 25. Annual report, 14 Aug 2026, page 58
- 26. Earnings call, 10 Aug 2026, page 16
- 27. Earnings call, 10 Aug 2026, page 17
- 28. Earnings call, 10 Aug 2026, page 5
- 29. Investor presentation, 7 Aug 2026, page 22
- 30. Investor presentation, 7 Aug 2026, page 23
- 31. Investor presentation, 7 Aug 2026, page 23
- 32. Earnings call, 10 Aug 2026, page 5
- 33. Earnings call, 10 Aug 2026, page 5
- 34. Earnings call, 10 Aug 2026, page 3
- 35. Exchange filing, 26 Jun 2026, page 2
- 36. Exchange filing, 6 Nov 2025, page 1
- 37. Investor presentation, 7 Aug 2026, page 15
- 38. Annual report, 14 Aug 2026, page 32
- 39. Annual report, 14 Aug 2026, page 33
- 40. Exchange filing, 16 Jun 2026, page 2
- 41. Annual report, 14 Aug 2026, page 123
Results
Consolidated; ₹ crore.Poly Medicure quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +18.3%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −11.9%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹525 Crdown 1.71%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹85 Crup 31.11%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 16.2%
Revenue by quarter
Peak revenue ₹535 Cr, quarter to Mar 2026; lowest ₹403 Cr, quarter to Jun 2025
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 420 | 424 | 441 | 403 | 444 | 494 | 535 | 525 |
| Net profit | 87 | 85 | 92 | 93 | 92 | 71 | 65 | 85 |
| Net margin | 20.8% | 20.1% | 20.8% | 23.1% | 20.7% | 14.3% | 12.2% | 16.2% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹1,875 Crup 12.30%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹321 Crdown 5.27%
- Net margin
- 17.1%
Revenue by year
Peak revenue ₹1,875 Cr, year to Mar 2026; lowest ₹455 Cr, year to Mar 2017
Net profit by year, a loss in red
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 455 | 522 | 611 | 687 | 786 | 923 | 1,115 | 1,376 | 1,670 | 1,875 |
| Net profit | 52 | 71 | 65 | 96 | 136 | 147 | 179 | 258 | 339 | 321 |
| Net margin | 11.5% | 13.5% | 10.7% | 14.0% | 17.3% | 15.9% | 16.1% | 18.8% | 20.3% | 17.1% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Manufacturing of Medical Devices, which carries all its revenue.
Valuation
Today, against the company's own history.Poly Medicure PE ratio and valuation
Price to earnings
At or below today's level on 47% of 2,479 trading days over the last 10 years.
LowestHighest
Its median49.11Industry median21.13
Price to book
At or below today's level on 5% of 1,890 trading days since Nov 2018.
LowestHighest
Its median7.94Industry median2.46
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 43% of 2,477 trading days over the last 10 years.
LowestHighest
Its median0.27%Industry median0.29%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −46.7% | −4.9% | −44.2% | 0.3% |
| 3 years | +7.9% | +19.4% | −9.8% | 0.2% |
| 5 years | +7.9% | +17.5% | −8.4% | 0.2% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Mutual fund holdings
75 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 50 of the 54 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 75 funds holding Poly Medicure
- AddedAdded. Funds that held more shares than at the end of the month before.
- 19
- CutCut. Funds that held fewer shares than at the end of the month before.
- 35
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 21
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 1
| Fund | |||
|---|---|---|---|
 quant Small Cap Fundquant Mutual Fund | 43,57,016 | 2.05% | ₹729.3 Cr |
 UTI Flexi Cap FundUTI Mutual Fund | 13,63,413 | 1.01% | ₹228.2 Cr |
 HSBC Midcap FundHSBC Mutual Fund | 12,33,816 | 1.23% | ₹206.5 Cr |
 SBI Healthcare Opportunities FundSBI Mutual Fund | 6,40,000 | 1.82% | ₹107.1 Cr |
| SBI MNC FundSBI Mutual Fund | 5,60,000 | 1.47% | ₹93.7 Cr |
 WhiteOak Capital Flexi Cap FundWhiteOak Capital Mutual Fund | 2,76,291 | 0.50% | ₹46.2 Cr |
| quant Multi Cap Fundquant Mutual Fund | 2,64,798 | 0.59% | ₹44.3 Cr |
 Invesco India Large Cap FundInvesco Mutual Fund | 1,73,600 | 1.51% | ₹29.1 Cr |
| WhiteOak Capital Mid Cap FundWhiteOak Capital Mutual Fund | 1,55,414 | 0.35% | ₹26.0 Cr |
| WhiteOak Capital Multi Cap FundWhiteOak Capital Mutual Fund | 1,46,104 | 0.57% | ₹24.5 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 31 Oct 2025.Poly Medicure insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Others: no market trade
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Poly Medicure competitors and peers
Medical Equipment & Supplies, 27 listed companies, priced on 30 Oct 2026. The table lists the 8 companies closest to Poly Medicure in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Molbio DiagnosticsMOLBIO | 14,682 | – | – | – | – | – | – | 0.00% |
 Sahajanand Medical TechnologiesSMT | 4,703 | – | – | – | – | – | – | 0.00% |
 Fischer Medical VenturesFISCHER | 1,732 | 57.85 | – | +196.0% | +354.6% | 8.3% | 10.2% | 0.20% |
 Tarsons ProductsTARSONS | 1,548 | 139.55 | 2.44 | +10.6% | −59.7% | 1.8% | 1.5% | 0.00% |
 Q-Line BiotechQLINE | 1,196 | 21.47 | – | – | – | 22.6% | – | 0.00% |
 Laxmi DentalLAXMIDENTL | 977 | 31.64 | 4.02 | – | – | 13.7% | 12.0% | 0.00% |
 Hemant Surgical IndustriesHSIL | 834 | 45.84 | – | +117.4% | +126.2% | 18.1% | – | 0.00% |
 Vasa DenticityDENTALKART | 761 | – | 4.37 | – | – | – | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Poly Medicure dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹3.50 a share, years to Mar 2025 and Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 28 Aug 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹3.50 |
| 18 Sep 2025 | Final | ₹3.50 |
| 19 Sep 2024 | Final | ₹3.00 |
| 21 Sep 2023 | Final | ₹3.00 |
| 16 Sep 2022 | Final | ₹2.50 |
| 16 Sep 2021 | Final | ₹2.50 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Poly Medicure announcements
Oct 2026
31 Oct · Analysts
Sep 2026
24 Sep · General Updates
23 Sep
21 Sep
18 Sep
Poly Medicure share price by year
Each calendar year to 2025.Poly Medicure share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,773.70 | −32.2% | 2,842.65 | 1,698.70 |
| 2024 | 2,615.25 | +75.5% | 3,128.90 | 1,390.55 |
| 2023 | 1,489.90 | +65.9% | 1,666.75 | 832.55 |
| 2022 | 897.85 | −6.3% | 1,031.35 | 667.75 |
| 2021 | 957.95 | +89.2% | 1,133.15 | 506.55 |
| 2020 | 506.20 | +132.1% | 536.25 | 202.85 |
| 2019 | 218.05 | −1.9% | 228.05 | 168.85 |
| 2018 | 222.20 | −20.4% | 290.00 | 191.15 |
| 2017 | 279.25 | +46.6% | 304.00 | 189.30 |
| 2016 | 190.45 | −4.5% | 215.28 | 124.28 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 29 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 29 Oct 2026 | 1,480.00 | 1,480.20 | 1,446.10 | 1,461.90 | 1,458.60 | 36,087 | 50.2% |
| 28 Oct 2026 | 1,465.00 | 1,489.90 | 1,454.90 | 1,476.00 | 1,476.97 | 73,752 | 69.7% |
| 27 Oct 2026 | 1,443.50 | 1,473.50 | 1,401.50 | 1,470.00 | 1,459.64 | 32,118 | 47.6% |
| 26 Oct 2026 | 1,450.00 | 1,460.80 | 1,426.50 | 1,443.50 | 1,445.18 | 43,418 | 50.6% |
| 23 Oct 2026 | 1,441.70 | 1,455.80 | 1,403.20 | 1,444.00 | 1,430.43 | 86,156 | 49.1% |
| 22 Oct 2026 | 1,464.90 | 1,517.80 | 1,431.50 | 1,448.90 | 1,474.50 | 1,95,822 | 40.5% |
| 21 Oct 2026 | 1,545.00 | 1,554.00 | 1,455.10 | 1,470.10 | 1,477.73 | 1,97,058 | 68.6% |
| 19 Oct 2026 | 1,594.90 | 1,594.90 | 1,543.00 | 1,550.70 | 1,558.53 | 55,799 | 44.1% |
| 16 Oct 2026 | 1,578.80 | 1,601.10 | 1,575.10 | 1,593.80 | 1,593.35 | 45,455 | 49.4% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus shares and stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 24 Mar 2017 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
| 2 Feb 2015 | Split | 0.5000 | Each share became 2. |
| 9 Jul 2013 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
| 26 Mar 2010 | Price move | – | Between two trading sessions the price fell 47% or more, or rose 90% or more. No corporate action is on record. Earlier prices are not shown. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Where an event has no factor that can be worked out, the chart leaves out the closes before it.
Company details
- NSE symbol
- POLYMED
- BSE code
- 531768
- ISIN
- INE205C01021
- Industry
- Healthcare Equipment & Supplies
- Website
- www.polymedicure.com
- CIN
- L40300DL1995PLC066923
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1995
- Registered office
- 232 B, 3rd Floor, Okhla Industrial Estate, Phase-III, New Delhi 110020, Delhi
- Share registrar
- MAS Services Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 500, BSE 500, Nifty Smallcap 250, BSE 250 SmallCap Index, BSE SmallCap, Nifty Total Market